Results 121 to 130 of about 1,466,333 (379)

CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

Cancer immunology research, 2020
Antibody agonists that target T-cell costimulatory pathways are being tested in the clinic. FS120, a dual agonist antibody specific for CD137 and OX40, delays tumor growth by improving the activation and proliferation of peripheral T cells. Following the
Miguel Gaspar, J. Pravin, L. Rodrigues, Sandra Uhlenbroich, K. L. Everett, F. Wollerton, Michelle Morrow, M. Tuna, N. Brewis   +8 more
semanticscholar   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Improvement of Radioimmunotherapy Using Pretargeting [PDF]

, 2013
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabeled monoclonal antibodies and receptor binding agents.
Caroline Bodet-Milin, Caroline Rousseau, Eric Frampas, Françoise Kraeber-Bodéré, Jacques Barbet, Jean-Francois Chatal   +5 more
core   +1 more source

Engineering antibodies with cancer‐associated binding sites

BMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian, Yumeng Pan, Yingchun Zhang, Fangling Wang, Zejun Wang   +4 more
wiley   +1 more source

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy

Cancer Management and Research, 2021
Jie Liang,1 Huihui Zhang,1 Yue Huang,1 Lilv Fan,1 Fanlin Li,1 Min Li,1 Yaping Yan,1 Junshi Zhang,1 Zeyu Li,1 Xuanming Yang1,2 1Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University ...
Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X   +9 more
doaj  

Immunity against fungal beta 1,3 glucan carbohydrate in the gastrointestinal tract [PDF]

, 2016
Inflammatory Bowel Disease (IBD) is a debilitating, life- long disease that affects about 1.4 millions Americans. Little is known about the pathogenesis of IBD and an effective cure still remains to be discovered.
Feliu, Marianela
core   +1 more source

Antibody fragments as probe in biosensor development [PDF]

, 2008
Today's proteomic analyses are generating increasing numbers of biomarkers, making it essential to possess highly specific probes able to recognize those targets.
Bonroy, Kristien, Huang, Lieven, Muyldermans, Serge, Saerens, Dirk   +3 more
core   +3 more sources

Techno‐economic analysis of membrane‐based continuous capture chromatography platforms for large‐scale antibody production

Biotechnology Progress, EarlyView.
Abstract Continuous manufacturing platforms and membrane chromatography are process technologies with the potential to reduce production costs and minimize process variability in monoclonal antibody production. This study presents a simulation and optimization framework to perform techno‐economic analyses of these strategies.
Juan J. Romero, Eleanor W. Jenkins, Marc R. Birtwistle, Scott M. Husson   +3 more
wiley   +1 more source

Antibody engineering for increased potency, breadth and half-life [PDF]

, 2015
Purpose of review: This review highlights recent developments in HIV-1 antibody engineering and discusses the effects of increased polyreactivity on serum half-lives of engineered antibodies.
Bjorkman, Pamela J., Scharf, Louise, Sievers, Stuart A., West, Anthony P., Jr.   +3 more
core   +1 more source

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

Nature Communications, 2020
T-cell bispecific antibodies (TCBs) crosslink tumor and T-cells to induce tumor cell killing. While TCBs are very potent, on-target off-tumor toxicity remains a challenge when selecting targets. Here, we describe a protease-activated anti-folate receptor
M. Geiger, K. Stubenrauch, J. Sam, W. Richter, Gregor Jordan, J. Eckmann, C. Hage, V. Nicolini, A. Freimoser-Grundschober, Mirko Ritter, M. Lauer, H. Stahlberg, P. Ringler, Jigar Patel, Eric Sullivan, Sandra Grau-Richards, S. Endres, S. Kobold, P. Umaña, P. Brünker, C. Klein   +20 more
semanticscholar   +1 more source